Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topefilgrastim in High-Risk Pregnant Patients With Preeclampsia
NCT07384936Not yet recruiting
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Open-label trial of topegfilgrastim in preeclampsia (3 arms). Primary endpoints: soluble fms-like tyrosine kinase-1, placental growth factor and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
topegfilgrastim
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07384936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384936.